Afficher la couverture 'Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience | D’amico, Ferdinando' en grand format
/5

0 avis

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience

Archive ouverte

D’amico, Ferdinando | Parigi, Tommaso Lorenzo | Fiorino, Gionata | Peyrin-Biroulet, Laurent | Danese, Silvio

Edité par CCSD ; Sage Publishing -

International audience. Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.

Consulter en ligne

Suggestions

Du même auteur

Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group

Archive ouverte | D’amico, Ferdinando | CCSD

International audience

Defining difficult-to-treat inflammatory bowel disease: why and how

Archive ouverte | Danese, Silvio | CCSD

International audience

Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13

Archive ouverte | Parigi, Tommaso Lorenzo | CCSD

International audience. Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Inflixima...

Chargement des enrichissements...